Actively Recruiting
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Led by Case Comprehensive Cancer Center · Updated on 2026-05-05
90
Participants Needed
2
Research Sites
98 weeks
Total Duration
On this page
Sponsors
C
Case Comprehensive Cancer Center
Lead Sponsor
T
The Cleveland Clinic
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participants will consist of individuals who have received radiation therapy in the past and were diagnosed with radiation necrosis, individuals with recurrent tumors, individuals with previously untreated tumors, and healthy individuals who have no brain diseases and have not had radiation treatment to the brain. Participants will undergo an MRI scan at a one-time research study visit; no extra tests or procedures will be required for this research study. The primary objectives of this study are: * To demonstrate the clinical feasibility of combining MRF with state-of-the-art parallel imaging techniques to achieve high-resolution quantitative imaging within a reasonable scan time of 5 min for whole brain coverage. * To apply the developed quantitative approach in combination with IVIM MRI for differentiation of tumor recurrence and radiation necrosis. * To investigate the effect of radiation dose on the development of radiation necrosis and tumor recurrence.
CONDITIONS
Official Title
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages 18 to 60 years
- No history of cerebrovascular disease for healthy participants
- No cognitive impairments for healthy participants
- Able to provide informed consent
- Biopsy-proven recurrent tumor or radiation necrosis, or PET identified or highly suspicious cases confirmed by tumor board or physician
- ECOG performance status 0-2
- Life expectancy greater than 6 months
- Radiology identified primary gliomas tumor or brain metastases, or PET identified or highly suspicious cases confirmed by tumor board
- No prior radiation or surgical treatment for brain metastases or primary glioma
- Radiology identified resectable meningioma
- No prior radiation or surgical treatment for brain lesions
- Age 18 years or older
- Participants with extracranial metastatic disease or prior/current systemic therapies will be evaluated on a case-by-case basis
You will not qualify if you...
- Pregnant or lactating women
- Presence of ferromagnetic or non-MRI compatible aneurysm clips
- Metal implants or medical devices incompatible with MRI, including pacemakers and defibrillators
- Embedded foreign metallic objects such as bullets, shrapnel, or metal fragments
- Severe claustrophobia
- Unable to lie still in the MRI scanner for 30 minutes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
2
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
L
Lan Lu, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here